Wogonoside is widely studied for its anti-inflammatory and neuroprotective properties, making it a compound of interest in the development of treatments for neurological disorders such as Alzheimer's and Parkinson's disease. It has shown potential in reducing oxidative stress and inhibiting the activation of microglial cells, which play a key role in neuroinflammation. In cancer research, wogonoside exhibits antiproliferative effects against various tumor cell lines, including liver, breast, and colorectal cancers. It induces apoptosis and cell cycle arrest, suggesting its role as a supportive agent in oncology. It also demonstrates hepatoprotective effects, helping protect liver cells from damage caused by toxins and reducing markers of liver injury in preclinical models. Due to its ability to modulate signaling pathways like NF-κB and MAPK, it is explored for use in chronic inflammatory conditions and autoimmune diseases. Additionally, wogonoside has been investigated for its antiviral activity, particularly against hepatitis B virus, showing suppression of viral replication in cell cultures. Its broad bioactivity profile supports its potential in pharmaceutical and nutraceutical applications, especially in formulations aimed at inflammation, neurodegeneration, and liver health.